Lauxera Capital Partners
VC
2020
$1 000 M
Paris, France
Investment Ticket
Investment Horizon
Investment Stage
Exit Strategy
Profile
Lauxera Capital Partners is a Healthtech growth investor with offices in Paris and San Francisco. The firm was founded by Victor Decrion, who serves as Managing Partner, together with co-founders Pierre Moustial, Samuel Levy, and Alex Slack. The team is 16 people across investing, operations, investor relations, and ESG. Lauxera works only with founders who have already built a profitable business and need help scaling - going global, hiring senior operators, and bolt-on M&A.
The firm invests only in Healthtech. That means medical devices, pharma services, digital health, healthcare software and data, and life science tools. Tickets are $10-50M at Series A through late-stage. Mandate is global - North America, Europe, and Asia. Total AUM is over $1B. Lauxera Growth II is the latest fund, closed at $572M in May 2026, above target. Fund I launched in 2021. Lauxera also funds rare-disease research through a charity partnership with Institut Imagine.
Notable investments: OrganOx - organ preservation. Antaros Medical - drug imaging. Verdot - bioprocessing. Acandis - devices for stroke and aneurysms. Biolamina - cell culture matrices. Caresyntax - surgical data.
Industry
Region of investment
Lauxera Capital Partners Funds
| Name | Type |
|
|
|
Size | AUM | Launch date |
|---|---|---|---|---|---|---|---|
|
Lauxera Growth II
|
Venture Capital (VC)
|
Digital
Healthcare Services
Medical Devices
Pharmaceuticals
Software
MedTech
Life Sciences
HealthTech
|
Late Stage (Series C+)
|
North America
Europe
Asia
|
$10-50 m
|
$572 M
|
May 2026
|
|
Lauxera Growth I Fund
|
Private Equity (PE)
|
Healthcare Services
Software
HealthTech
|
Series B
Late Stage (Series C+)
|
North America
Europe
|
$5-10 m
|
$260 M
|
February 2022
|
